Lasmiditan

Research use only, not for human use.

Lasmiditan, also known as COL-144 and LY573144, is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist (K1=2.21 μM) without vasoconstrictor activity that seemed effective when given as an intravenous infusion in a proof-of-concept migraine study.

Lasmiditan, also known as COL-144 and LY573144, is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist (K1=2.21 μM) without vasoconstrictor activity that seemed effective when given as an intravenous infusion in a proof-of-concept migraine study. Lasmiditan showed efficacy in its primary endpoint, with a 2-hour placebo-subtracted headache response of 28.8%, though with frequent reports of dizziness, paresthesias, and vertigo.

COL-144; LY573144

Others

Other Targets

5-HT1F

Neurological Disease

——

439239-90-4

377.14

C19H18F3N3O2

98%

——

CN1CCC(CC1)C(=O)c1nc(ccc1)NC(=O)c1c(cc(cc1F)F)F

——

(-20℃)

With Ice Pack

≥ 2 years